Vitro Biopharma Announces Advances in Stem Cell Therapy without Transplants


Follow this company

Companies Mentioned

OTC:BB:VODG
06/10/2014 [ACCESSWIRE]

Golden, Colorado / ACCESSWIRE / June 10, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, has been pursuing the determination of therapeutic benefits derived from activation of adult stems residing within the human body. This approach is advantageous over transplantation since many of the complications are overcome including, effects of in-vitro stem cell expansion, effects of allogeneic cells and regulatory obstacles.  Recent research has validated and expanded the scope of this approach by reports of increased muscle performance & endurance as well as reported changes critical learning periods that may be due to activation of neural stem cells in the adult brain. It is thus likely that activation of adult stem cells leads to specific performance enhancement as is well-known for activation of blood (hematopoietic) stem cells by  growth factors that stimulate generation of red or white blood cells. We have published 2 new blogs providing more detail regarding stem cell therapy without transplants http://vitrobiopharma.com/2014/06/06/stem-cell-therapy-without-stem-cell-transplants-part-current-status/.

Vitro Biopharma has ongoing business with a network of European medical clinics treating patients with various conditions.  We provide extensive test measurements of numerous biological molecules within serum including cytokines, growth factors and other biological signaling molecules to generate a biomarker profile of diseases http://neuromics.blogspot.com/2014/05/autism-spectrum-disorder-asd-custom.html

This information allows comparison with other patients and also a basis for evaluating the effects of various treatments on disease. We are beginning trials of stem cell activating agents by determining their effects on biomarker profiles and clinical status.  We are also developing a Phase II clinical trial testing the effects of activation of neural stem cells on biomarker profile, stem cell mobilization and clinical effects in patients with traumatic brain injury (TBI).  There is substantial pre-clinical data showing that neural stem cell activation results in decreased lesion volume, decreased neural degeneration and increased motor coordination in a mouse model of TBI.

Dr. Jim Musick, Vitro Biopharma’s President & CEO said, “Adult stem cells exist within various locations in the human body as quiescent cells that respond to appropriate stimulation. Current research suggests that adult stem cells including MSCs, muscle stem cells and neural stem cells may be activated through exposure to specific substances.  This expands our understanding of stem cell activation.  While growth factors have been widely used to produce blood cells from hematopoietic stem cells for several years, it is also likely that other adult stem cells may be activated as well.  Harvard University researchers have recently shown that serum protein, PDF11 is largely responsible for age reversal effects of young blood by activating muscle stem cells resulting in increased muscle performance.  (Science 344: 649, 2014).   These and other results open the possibility of stem cell therapy without transplants.  While there are clear situations where transplants are most appropriate, activation of latent stem cells affords another option that can be pursued while transplantation is further developed..  There is a clear pathway to testing therapeutic and performance benefits through controlled clinical studies.  We are now developing cell-based assays of stem cell proliferation, migration and reprogramming for discovery of new stem cell activation agents in addition to support of clinical trials and determination of possible synergistic effects of activation agents.”

Pete Shuster, a Director of Vitro Biopharma and the CEO & founder of Neuromics said “The excellent work being done by Jim and his team has opened up two new and predictable revenue sources for Vitro Biopharma. First, the assays developed to test the potency of our stem cell activating agents are excellent for stem cell based drug discovery. These assays can be used to test small molecules/compounds, for cell-based drug delivery and toxicity studies. We have a wealth of data available to support our value proposition. We are in the process of developing a plan to make these assays available to biopharma companies in a way that best fits their requirements. Secondly, we have started generating revenue by providing these tested activators to select clients in Europe. Initial therapeutic value is encouraging pending more testing after 3-6 months of treatment. We have plans to ramp up our stem cell activating products rapidly pending results. We anticipate these developments will enable Vitro Biopharma become cash flow positive in Q3 and consistently profitable starting in Q4, 2014.

About Vitro Biopharma

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG; http://www.vitrobiopharma.com/), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes.  In 2011, Vitro Biopharma out-licensed its intellectual property related to treatment of infertility to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies.  Vitro Biopharma also owns a pending patent for methods of mesenchymal stem cell (MSC) generation and related materials. Vitro Biopharma’s mission is “Harnessing the Power of Cells(tm)” for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado.  Vitro Biopharma manufactures and sells “Tools for Stem Cell and Drug Development(tm)”, including human mesenchymal stem cells and derivatives, the MSC-Gro(tm) Brand of optimized media for MSC self-renewal and lineage-specific differentiation.  In addition to our FSH patent licensee, Vitro Biopharma maintains several strategic partnerships including an alliance with Neuromics, Inc. (http://www.neuromics.com/).  Neuromics, Inc. is a primary distributor of Vitro Biopharma products and a well established manufacturer and distributor of a large variety of life science research products especially focused on cell-based assay systems We jointly manufacture stem cell assay systems with HemoGenix(r), Inc. (http://www.hemogenix.com/), known as the MSCglo quantitative assay for determination of MSC quality, potency and response to toxic agents.    Also, Vitro Biopharma’s CEO is a consultant on an NSF grant at the City College of New York to advise Dr. Lane Gilcrest, Professor of Materials Science and Engineering, and his colleagues regarding the development of novel extracellular materials for use in self-renewal and differentiation of mesenchymal stem cells.

Safe Harbor Statement

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures.  Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission.  Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements.  Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James Musick
Chief Executive Officer
Vitro Biopharma
(303) 999-2130 Ext. 3
E-mail: jim@vitrobiopharma.com

 

Source: Vitro Diagnostics, Inc.

COMMENTS

Leave a comment...
 * 

Your Name
 *